UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 176

Sortiert nach

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

Annals of oncology, 2011-07, Vol.22 (7), p.1535-1546

2011

Link zum Volltext

Verfügbarkeit prüfen

Transient MEK inhibitor-associated retinopathy in metastatic melanoma

Annals of oncology, 2014-07, Vol.25 (7), p.1437-1441

2014

Link zum Volltext

Verfügbarkeit prüfen

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition

British journal of cancer, 2014-10, Vol.111 (9), p.1788-1801

2014

Link zum Volltext

Verfügbarkeit prüfen

Interpreting progression-free survival and overall survival data in biosimilar clinical studies: considerations based on a recent rituximab biosimilar study

ANNALS OF ONCOLOGY, 2017-09, Vol.28, p.v361-v361

2017

Link zum Volltext

Verfügbarkeit prüfen

Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group

Annals of oncology, 2008-08, Vol.19 (8), p.1442-1449

2008

Link zum Volltext

Verfügbarkeit prüfen

Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trial

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.4003-4003

2007

Link zum Volltext

Verfügbarkeit prüfen

Equivalent efficacy of a biosimilar rituximab and reference rituximab in previously untreated advanced follicular lymphoma: Extended results of ASSIST-FL, a confirmatory phase III study

Annals of oncology, 2017-09, Vol.28, p.v355-v355

2017

Link zum Volltext

Verfügbarkeit prüfen

3004 ORAL Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastastic colorectal cancer (mCRC): a large-scale phase II study, OPUS

European journal of cancer supplements, , Vol.5 (4), p.236-236

Link zum Volltext

Verfügbarkeit prüfen

6079 Overall survival of patients with KRAS wild-type tumours treated with FOLFOX4± cetuximab as 1st-line treatment for metastatic colorectal cancer: The OPUS study

European journal of cancer supplements, 2009, Vol.7 (2), p.346-346

2009

Link zum Volltext

Verfügbarkeit prüfen

6078 Cetuximab plus FOLFIRI in 1st-line treatment of metastatic colorectal cancer: Quality of life (QoL) analysis of patients (pts) with KRAS wild-type (wt) tumours in the CRYSTAL trial

European journal of cancer supplements, 2009, Vol.7 (2), p.345-345

2009

Link zum Volltext

Verfügbarkeit prüfen

3003 ORAL Cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) failing prior oxaliplatin-based therapy: the EPIC trial

European journal of cancer supplements, 2007, Vol.5 (4), p.235-236

2007

Link zum Volltext

Verfügbarkeit prüfen

Overall Survival and Biomarker Results from a Phase 2 Study of Mek1/2 Inhibitor Binimetinib (Mek162) in Patients with Advanced Nras-Mutant Melanoma

Annals of oncology, 2014-09, Vol.25, p.v1

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD01-01: Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results of the Randomized Phase II BALI-1 Trial

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.PD01-01-PD01-01

2010

Link zum Volltext

Verfügbarkeit prüfen

Cetuximab plus FOLFIRI first line in patients (pts) with metastatic colorectal cancer (mCRC): A quality-of-life (QoL) analysis of the CRYSTAL trial

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.4076-4076

2009

Link zum Volltext

Verfügbarkeit prüfen

Transient MEK inhibitor-associated retinopathy in metastatic melanoma

Annals of oncology, 2014-07, Vol.25 (7), p.1437

2014

Link zum Volltext

Verfügbarkeit prüfen

Cetuximab in combination with weekly 5-fluorouracil/ folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer : a phase Ib/II study of the AIO Gl Group

Annals of oncology, 2008, Vol.19 (8), p.1442-1449

2008

Link zum Volltext

Verfügbarkeit prüfen

Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.4035-4035

2007

Link zum Volltext

Verfügbarkeit prüfen

Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of 800 patients in a randomized phase III trial (EPIC)

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.3556-3556

2006

Link zum Volltext

Verfügbarkeit prüfen

Optimal dose of cetuximab (C) given every 2 weeks (q2w): A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.3085-3085

2006

Link zum Volltext

Verfügbarkeit prüfen

LBA35OVERALL SURVIVAL AND BIOMARKER RESULTS FROM A PHASE 2 STUDY OF MEK1/2 INHIBITOR BINIMETINIB (MEK162) IN PATIENTS WITH ADVANCED NRAS-MUTANT MELANOMA

Annals of oncology, 2014-09, Vol.25 (suppl_4)

2014

Link zum Volltext

Verfügbarkeit prüfen

Anisotropic etching of Si

Journal of micromechanics and microengineering, 2019-09, Vol.29 (9), p.93002

Zubel, Irena

2019

Link zum Volltext

Verfügbarkeit prüfen

Effect of cations on silicon anisotropic etching process in solutions containing TMAH and TMAH with tensioactive compounds

Sensors and actuators. A. Physical., 2020-03, Vol.303, p.111829, Article 111829

Zubel, Irena

2020

Link zum Volltext

Verfügbarkeit prüfen

From decolonization to destalinization: Aimé Césaire and the "Polish question"

Journal of postcolonial writing, 2023-03, Vol.59 (2), p.157-171

Zubel, Marla

2023

Link zum Volltext

Verfügbarkeit prüfen

Remembering the Global ‘60s: A View from Eastern Europe

Cultural critique, 2019-03, Vol.103 (103), p.36

Zubel, Marla

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 176

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(137)
Mit Volltextzugriff
(148)

Publikationsform

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(84)
Life Sciences & Biomedicine
(40)
Technology
(39)
Humans
(38)
Engineering
(31)
Engineering, Electrical & Electronic
(25)
Female
(25)
Physical Sciences
(24)
Physics
(24)
Male
(21)
Middle Aged
(20)
Aged
(19)
Exact Sciences And Technology
(19)
Adult
(18)
Instruments & Instrumentation
(18)
Animals
(15)
Oncology
(15)
Silicon
(14)
Anisotropic Etching
(13)
Materials Science
(11)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

Transient MEK inhibitor-associated retinopathy in metastatic melanoma

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition

Interpreting progression-free survival and overall survival data in biosimilar clinical studies: considerations based on a recent rituximab biosimilar study

Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group

Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trial

Equivalent efficacy of a biosimilar rituximab and reference rituximab in previously untreated advanced follicular lymphoma: Extended results of ASSIST-FL, a confirmatory phase III study

3004 ORAL Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastastic colorectal cancer (mCRC): a large-scale phase II study, OPUS

6079 Overall survival of patients with KRAS wild-type tumours treated with FOLFOX4± cetuximab as 1st-line treatment for metastatic colorectal cancer: The OPUS study

6078 Cetuximab plus FOLFIRI in 1st-line treatment of metastatic colorectal cancer: Quality of life (QoL) analysis of patients (pts) with KRAS wild-type (wt) tumours in the CRYSTAL trial

3003 ORAL Cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) failing prior oxaliplatin-based therapy: the EPIC trial

Overall Survival and Biomarker Results from a Phase 2 Study of Mek1/2 Inhibitor Binimetinib (Mek162) in Patients with Advanced Nras-Mutant Melanoma

Abstract PD01-01: Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results of the Randomized Phase II BALI-1 Trial

Cetuximab plus FOLFIRI first line in patients (pts) with metastatic colorectal cancer (mCRC): A quality-of-life (QoL) analysis of the CRYSTAL trial

Transient MEK inhibitor-associated retinopathy in metastatic melanoma

Cetuximab in combination with weekly 5-fluorouracil/ folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer : a phase Ib/II study of the AIO Gl Group

Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study

Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of 800 patients in a randomized phase III trial (EPIC)

Optimal dose of cetuximab (C) given every 2 weeks (q2w): A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC)

LBA35OVERALL SURVIVAL AND BIOMARKER RESULTS FROM A PHASE 2 STUDY OF MEK1/2 INHIBITOR BINIMETINIB (MEK162) IN PATIENTS WITH ADVANCED NRAS-MUTANT MELANOMA

Anisotropic etching of Si

Effect of cations on silicon anisotropic etching process in solutions containing TMAH and TMAH with tensioactive compounds

From decolonization to destalinization: Aimé Césaire and the "Polish question"

Bridging Thrombolysis versus Direct Mechanical Thrombectomy in Stroke Due to Basilar Artery Occlusion

Remembering the Global ‘60s: A View from Eastern Europe

Suchergebnisse filtern